Novavax’s Production Problems Are Overblown, Says Analyst_老虎社区_美港股上老虎

Novavax’s Production Problems Are Overblown, Says Analyst

TipRanks2021-03-30

Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Alfred1007
·2021-03-30
Who will get more market share?
回复
点赞
举报
nakazatous
·2021-03-30
Reply my comment
回复
1
举报
收起
- Jchptan:
  Comment back pls
  2021-03-30
  回复
  举报
- KLS:
  buy
  2021-03-30
  回复
  举报
vbjvvbb
·2021-03-30
Amazing...
回复
点赞
举报
jimmylaw
·2021-03-30
Ohhhh nooo
回复
1
举报
trollololol
·2021-03-30
Like and reply please
回复
4
举报
收起
- nakazatous:
  Ok
  2021-03-30
  回复
  举报
3a5bc973
·2021-03-30
Oh no
回复
3
举报
收起
- PickaChew:
  Hi
  2021-03-30
  回复
  举报
shaunlohloh
·2021-03-30
Oh no
回复
1
举报
joeyong
·2021-03-30
comment pls!
回复
5
举报
收起
- pav:
  Pls do same
  2021-03-30
  回复
  举报
- nakazatous:
  Ok
  2021-03-30
  回复
  举报
mumu b
·2021-03-30
Hahaha
回复
4
举报
收起
- mumu b:
  goooooo
  2021-04-01
  回复
  举报
609b13a
·2021-03-30
Zz
回复
2
举报
收起
- Hoxyn:
  SMh
  2021-03-31
  回复
  举报
boonhuat
·2021-03-30
Coin
回复
3
举报
AlexWong
·2021-03-30
Drop more, please so I can buy!
回复
4
举报
收起
- boonhuat:
  coin
  2021-03-30
  回复
  举报
Zarkness
·2021-03-30
Obviously , market hit you hard when it’s volatile .
回复
4
举报
收起
- dandan_4896:
  I love all of u tiger traders. Do u love me???
  2021-03-30
  回复
  举报
- 609b13a:
  Oww
  2021-03-30
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2123265703?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","is_english":true,"pubTime":"2021-03-30 11:46","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2123265703","market":"us","top_or_hot":-1,"title":"Novavax’s Production Problems Are Overblown, Says Analyst","media":"TipRanks","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","article_id":"2123265703","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","pubTimestamp":1617075962,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"分析师称，诺瓦瓦克斯医药的生产问题被夸大了","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":355536972,"gmtCreate":1617083432096,"gmtModify":1634522741803,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570656625926041","authorIdStr":"3570656625926041"},"htmlText":"Who will get more market share?","listText":"Who will get more market share?","text":"Who will get more market share?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355536972","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":355590462,"gmtCreate":1617081444956,"gmtModify":1634522753035,"author":{"id":"3570519374633708","authorId":"3570519374633708","name":"nakazatous","avatar":"https://static.tigerbbs.com/9ac34656b654252df0f82999785e92ae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570519374633708","authorIdStr":"3570519374633708"},"htmlText":"Reply my comment","listText":"Reply my comment","text":"Reply my comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/355590462","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3919027,"gmtCreate":1617081644224,"gmtModify":1635746640607,"authorId":3547639144615679,"author":{"id":3547639144615679,"idStr":"3547639144615679","authorId":3547639144615679,"name":"Jchptan","avatar":"https://static.tigerbbs.com/d97f1aa10a314dfb46a4e618e4f46ac6","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355590462,"type":1,"supId":0,"prevId":0,"content":"Comment back pls","text":"Comment back pls","html":"Comment back pls"},{"id":3919048,"gmtCreate":1617081911069,"gmtModify":1635746639084,"authorId":3551655093075927,"author":{"id":3551655093075927,"idStr":"3551655093075927","authorId":3551655093075927,"name":"KLS","avatar":"https://static.tigerbbs.com/60fe00969bbce4cfecf0d17a38c77628","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355590462,"type":1,"supId":0,"prevId":0,"content":"<u>buy</u>","text":"<u>buy</u>","html":"<u>buy</u>"}],"langContent":"EN"},{"id":355507904,"gmtCreate":1617081303108,"gmtModify":1634522754094,"author":{"id":"3554803619527377","authorId":"3554803619527377","name":"vbjvvbb","avatar":"https://static.tigerbbs.com/8fb1b38f4354ec237a7cab99dbd46e94","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3554803619527377","authorIdStr":"3554803619527377"},"htmlText":"Amazing...","listText":"Amazing...","text":"Amazing...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355507904","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":355501815,"gmtCreate":1617080674437,"gmtModify":1634522757696,"author":{"id":"3570772304712620","authorId":"3570772304712620","name":"jimmylaw","avatar":"https://static.tigerbbs.com/f6c847ae11f03f4682632e6fa4016040","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3570772304712620","authorIdStr":"3570772304712620"},"htmlText":"Ohhhh nooo","listText":"Ohhhh nooo","text":"Ohhhh nooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355501815","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":355509391,"gmtCreate":1617080526513,"gmtModify":1634522759250,"author":{"id":"3575040910386797","authorId":"3575040910386797","name":"trollololol","avatar":"https://static.tigerbbs.com/bb3709f9470a5163c6c7031ab692e8c9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575040910386797","authorIdStr":"3575040910386797"},"htmlText":"Like and reply please","listText":"Like and reply please","text":"Like and reply please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/355509391","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3919001,"gmtCreate":1617081456299,"gmtModify":1635746642651,"authorId":3570519374633708,"author":{"id":3570519374633708,"idStr":"3570519374633708","authorId":3570519374633708,"name":"nakazatous","avatar":"https://static.tigerbbs.com/9ac34656b654252df0f82999785e92ae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355509391,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":355276514,"gmtCreate":1617080133038,"gmtModify":1634522762753,"author":{"id":"3573385929982547","authorId":"3573385929982547","name":"3a5bc973","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573385929982547","authorIdStr":"3573385929982547"},"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/355276514","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3919180,"gmtCreate":1617083223289,"gmtModify":1635746630494,"authorId":3575623648551699,"author":{"id":3575623648551699,"idStr":"3575623648551699","authorId":3575623648551699,"name":"PickaChew","avatar":"https://static.tigerbbs.com/e64125a635ce42e8dfd601284ad29438","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355276514,"type":1,"supId":0,"prevId":0,"content":"<u>Hi</u>","text":"<u>Hi</u>","html":"<u>Hi</u>"}],"langContent":"EN"},{"id":355271482,"gmtCreate":1617079969946,"gmtModify":1634522764018,"author":{"id":"3554971279962368","authorId":"3554971279962368","name":"shaunlohloh","avatar":"https://static.tigerbbs.com/d9417d251e570e152139797ec05b5914","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3554971279962368","authorIdStr":"3554971279962368"},"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355271482","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":355279813,"gmtCreate":1617079800532,"gmtModify":1634522765533,"author":{"id":"3577335802381292","authorId":"3577335802381292","name":"joeyong","avatar":"https://static.tigerbbs.com/966871dcabda9a3a4a0d39efe600dd1c","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3577335802381292","authorIdStr":"3577335802381292"},"htmlText":"comment pls!&nbsp;","listText":"comment pls!&nbsp;","text":"comment pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/355279813","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3918824,"gmtCreate":1617079850730,"gmtModify":1635746655173,"authorId":3554815368592867,"author":{"id":3554815368592867,"idStr":"3554815368592867","authorId":3554815368592867,"name":"pav","avatar":"https://static.tigerbbs.com/0aba91967ed3feb5ab1c0cffcb3c5b91","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355279813,"type":1,"supId":0,"prevId":0,"content":"Pls do same","text":"Pls do same","html":"Pls do same"},{"id":3919002,"gmtCreate":1617081462774,"gmtModify":1635746642542,"authorId":3570519374633708,"author":{"id":3570519374633708,"idStr":"3570519374633708","authorId":3570519374633708,"name":"nakazatous","avatar":"https://static.tigerbbs.com/9ac34656b654252df0f82999785e92ae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355279813,"type":1,"supId":3918824,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":355241402,"gmtCreate":1617079305406,"gmtModify":1634522771232,"author":{"id":"3575932421297543","authorId":"3575932421297543","name":"mumu b","avatar":"https://static.tigerbbs.com/56c45ab59e10dbc9641137a77ea4b010","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575932421297543","authorIdStr":"3575932421297543"},"htmlText":"Hahaha","listText":"Hahaha","text":"Hahaha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/355241402","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3937021,"gmtCreate":1617254942614,"gmtModify":1635745593280,"authorId":3575932421297543,"author":{"id":3575932421297543,"idStr":"3575932421297543","authorId":3575932421297543,"name":"mumu b","avatar":"https://static.tigerbbs.com/56c45ab59e10dbc9641137a77ea4b010","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355241402,"type":1,"supId":0,"prevId":0,"content":"<u>goooooo</u>","text":"<u>goooooo</u>","html":"<u>goooooo</u>"}],"langContent":"EN"},{"id":355254204,"gmtCreate":1617078853408,"gmtModify":1634522773494,"author":{"id":"3574158219076158","authorId":"3574158219076158","name":"609b13a","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574158219076158","authorIdStr":"3574158219076158"},"htmlText":"Zz","listText":"Zz","text":"Zz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/355254204","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3931013,"gmtCreate":1617197454272,"gmtModify":1635745979666,"authorId":3573824146229547,"author":{"id":3573824146229547,"idStr":"3573824146229547","authorId":3573824146229547,"name":"Hoxyn","avatar":"https://static.tigerbbs.com/69c90aca320bde7e33f469150d40df06","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355254204,"type":1,"supId":0,"prevId":0,"content":"SMh","text":"SMh","html":"SMh"}],"langContent":"EN"},{"id":355252048,"gmtCreate":1617078622384,"gmtModify":1634522775447,"author":{"id":"3575289521158838","authorId":"3575289521158838","name":"boonhuat","avatar":"https://static.tigerbbs.com/04020f90fcb6f74117e2a7d738a58fe0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575289521158838","authorIdStr":"3575289521158838"},"htmlText":"Coin","listText":"Coin","text":"Coin","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355252048","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":355228465,"gmtCreate":1617077400057,"gmtModify":1634522782973,"author":{"id":"3560730969024945","authorId":"3560730969024945","name":"AlexWong","avatar":"https://static.tigerbbs.com/5355aad69cfd852f084e4c841a5fb0b0","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3560730969024945","authorIdStr":"3560730969024945"},"htmlText":"Drop more, please so I can buy!","listText":"Drop more, please so I can buy!","text":"Drop more, please so I can buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/355228465","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3918659,"gmtCreate":1617078613742,"gmtModify":1635746668411,"authorId":3575289521158838,"author":{"id":3575289521158838,"idStr":"3575289521158838","authorId":3575289521158838,"name":"boonhuat","avatar":"https://static.tigerbbs.com/04020f90fcb6f74117e2a7d738a58fe0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355228465,"type":1,"supId":0,"prevId":0,"content":"<u>coin</u>","text":"<u>coin</u>","html":"<u>coin</u>"}],"langContent":"EN"},{"id":355229969,"gmtCreate":1617076893151,"gmtModify":1634522785386,"author":{"id":"3572916667219493","authorId":"3572916667219493","name":"Zarkness","avatar":"https://static.tigerbbs.com/4b8c61830c4883c4232aece921d89d14","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3572916667219493","authorIdStr":"3572916667219493"},"htmlText":"Obviously , market hit you hard when it’s volatile .&nbsp;","listText":"Obviously , market hit you hard when it’s volatile .&nbsp;","text":"Obviously , market hit you hard when it’s volatile .","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/355229969","repostId":2123265703,"repostType":4,"repost":{"id":"2123265703","kind":"news","pubTimestamp":1617075962,"share":"https://www.laohu8.com/m/news/2123265703?lang=&edition=full","pubTime":"2021-03-30 11:46","market":"us","language":"en","title":"Novavax’s Production Problems Are Overblown, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265703","media":"TipRanks","summary":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine f","content":"<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax’s Production Problems Are Overblown, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax’s Production Problems Are Overblown, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/306ce9209cf24d2e0dd1d1612bc08dd9","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-production-problems-overblown-says-005502745.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123265703","content_text":"Reports of raw materials shortages causing production delays for Novavax's (NVAX) COVID-19 vaccine forced the company to postpone signing a supply contract with the European Union Thursday.As Reuters reported, the EU was hoping to order 100 million, or even 200 million doses of Novavax's two-dose vaccine, but now \"they are slowing down the process of finishing the contract.\" That news certainly spooked investors, sending Novavax shares tumbling.And yet, B. Riley analyst Mayank Mamtani is unafraid.Mamtani has spoken with Novavax executives and confirmed that the company's \"EU supply negotiations continue in parallel progression... in order to submit regulatory filing in the U.K. first, shortly followed by EMA to access several countries within the E.U.\"In other words, while there may be a delay in signing, the negotiations have not been called off by any means. To the contrary, says the analyst, Novavax is \"likely be negotiating from position of strength particularly given the relatively increased prominence of variants of concern, and increased skepticism for local vaccine manufacturers.\"Here, Mamtani obviously refers to the well-publicized problem of Europe's off-again, on-again, off-again endorsements of AstraZeneca's AZD1222 coronavirus vaccine over concerns that it may cause blood clots. But the analyst is also referring to a vaccine from CureVac, which he notes has suffered a delay in its \"interim readout\" into mid-Q2 2021, \"in order to account for protocol amendments to include analysis on specific variants.\"As Mamtani explains, the EU had wanted to buy CureVac's mRNA-based vaccine because trials of its effectiveness would have focused intensively on \"subjects in South America,\" where more infectious and more severe COVID-19 variants are running rampant. EU health officials wanted an mRNA vaccine proven effective against those variants, which are also gaining ground on the Continent, and had hoped that CureVac's CVnCoV would be \"the first mRNA-based vaccine exposed in a meaningful way to the U.K., S.A., and/or P1 strains in a clinical trial setting.\"But now deployment of it, like AstraZeneca's troubled vaccine, has been delayed -- creating Novavax's \"position of strength\" mentioned above.Meanwhile, on the subject of raw materials shortages delaying production of Novavax's NVX-CoV2373 vaccine, Mamtani considers any such delays only temporary in nature. As the analyst explains: \"enforcement of Defense Production Act would be able to soon flood the global supply chain markets with these relatively commoditized items.\"As a result, Mamtani continues to anticipate that NVX-CoV2373 will \"play a meaningful role in the Biden administration's ongoing vaccine diplomacy efforts recognizing the need for herd immunity to be attained at globally.\" The analyst predicts a 90% chance that NVX-CoV2373 will ultimately be approved for Emergency Use Authorization.So what's the upshot for investors? Mamtani is sticking to his Buy rating and $365 price target on the stock. In this analyst's view, there's still plenty of reason to hope that Novavax stock will more than double. (To watch Mamtani's track record, click here)The rest of the Street appears to echo Mamtani's bullish sentiment. As it has racked up 5 Buys and no Holds or Sells, the consensus is unanimous: NVAX is a Strong Buy. Adding to the good news, the upside potential lands at 86% based on the $323 average price target. (See NVAX stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3918517,"gmtCreate":1617077118699,"gmtModify":1635746677284,"authorId":3576232257279797,"author":{"id":3576232257279797,"idStr":"3576232257279797","authorId":3576232257279797,"name":"dandan_4896","avatar":"https://static.tigerbbs.com/d8b00e27a4dd6f248e38c3d78f21f188","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355229969,"type":1,"supId":0,"prevId":0,"content":"I love all of u tiger traders. Do u love me???","text":"I love all of u tiger traders. Do u love me???","html":"I love all of u tiger traders. Do u love me???"},{"id":3918695,"gmtCreate":1617078869513,"gmtModify":1635746665056,"authorId":3574158219076158,"author":{"id":3574158219076158,"idStr":"3574158219076158","authorId":3574158219076158,"name":"609b13a","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":355229969,"type":1,"supId":0,"prevId":0,"content":"Oww","text":"Oww","html":"Oww"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":49,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}